LabCorp Biorepository Receives Industry Accreditation from College of American Pathologists

  LabCorp Biorepository Receives Industry Accreditation from College of
  American Pathologists

Business Wire

BURLINGTON, N.C. -- January 9, 2013

Laboratory Corporation of America^® Holdings (LabCorp^®) (NYSE: LH) today
announced the recent accreditation of its Biorepository by the College of
American Pathologists (CAP). CAP’s inaugural accreditation program was
developed to establish internationally-recognized best practices and quality
standards for the collection, storage and future analysis of biospecimens.

The LabCorp Biorepository, located in Kannapolis, North Carolina adjacent to
the North Carolina Research Campus, is a world-class biological specimen
storage facility that LabCorp opened in 2009. Beyond simple storage
capabilities, the biorepository offers well-annotated, consented specimens
that are available for biomarker discovery efforts. Redundant back-up systems,
state-of-the-art validated informatics and on-site nucleic acid extraction
capabilities make LabCorp's Biorepository the facility of choice for
pharmaceutical and academic research specimen storage.

The CAPBiorepository Accreditation Program is a three-year, peer-based
accreditation program that was designed to strengthen the standard of patient
care by ensuring the consistent, verifiable quality ofbiospecimens for
clinical or research purposes. CAP accreditation requires passing a series of
inspections that review procedures for patient consent and the collection of
biospecimens, their processing and annotation, and their storage, transport
and distribution.

About LabCorp^®

Laboratory Corporation of America^® Holdings, an S&P 500 company, is a pioneer
in commercializing new diagnostic technologies and the first in its industry
to embrace genomic testing. With annual revenues of $5.5 billion in 2011, over
31,000 employees worldwide, and more than 220,000 clients, LabCorp offers more
than 4,000 tests ranging from routine blood analyses to reproductive genetics
to companion diagnostics. LabCorp furthers its scientific expertise and
innovative clinical testing technology through its LabCorp Specialty Testing
Group: The Center for Molecular Biology and Pathology, National Genetics
Institute, ViroMed Laboratories, Inc., The Center for Esoteric Testing,
Litholink Corporation, Integrated Genetics, Integrated Oncology, DIANON
Systems, Inc., Monogram Biosciences, Inc., Colorado Coagulation, and Endocrine
Sciences. LabCorp conducts clinical trials testing through its LabCorp
Clinical Trials division. LabCorp clients include physicians, government
agencies, managed care organizations, hospitals, clinical labs, and
pharmaceutical companies. To learn more about our organization, visit our Web
site at: www.labcorp.com.

This press release contains forward-looking statements. Each of the
forward-looking statements is subject to change based on various important
factors, including without limitation, competitive actions in the marketplace
and adverse actions of governmental and other third-party payors. Actual
results could differ materially from those suggested by these forward-looking
statements. Further information on potential factors that could affect
LabCorp’s financial results is included in the Company’s Form 10-K for the
year ended December 31, 2011, and subsequent SEC filings.

Contact:

Laboratory Corporation of America^® Holdings
Investor/Media Contact:
Stephen Anderson, 336-436-5076
www.labcorp.com
 
Press spacebar to pause and continue. Press esc to stop.